Celltrion to conduct clinical trials for Remsima in the U.S.

Celltrion said Monday it has filed an application of its antibody drug Remsima for the U.S. Food and Drug Administration in a bid to carry out its clinical tests there.

It will take about six months to receive the U.S. FDA’s approval for the clinical test, the company said.

Remsima is a biosimilar version of U.S. Merck’s Remicade, a globally renowned medication for rheumatoid arthritis.
...